Researchers conducted a study on the drug zodasiran, which targets a liver protein and significantly lowers triglyceride and lipoprotein levels in patients with mixed hyperlipidemia on statin therapy. The drug, an siRNA that silences the ANGPTL3 gene, showed promising results in reducing lipid levels and improving cardiovascular health. The reductions in liver fat content with zodasiran also suggest potential benefits for metabolic dysfunction-associated steatotic liver disease. Safety results were positive, with manageable adverse events reported. The study highlights the importance of diverse genetic research and suggests zodasiran’s potential in reducing the risk of coronary artery disease. Future phase 3 trials are planned.
Source link
Gene Silencing Benefit of Zodasiran in Hyperlipidemia
